Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advancing targeted protein degradation for cancer therapy
Brandon Dale, Meng Cheng, Kwang‐Su Park, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 638-654
Open Access | Times Cited: 428

Showing 1-25 of 428 citing articles:

The emerging role of mass spectrometry-based proteomics in drug discovery
Felix Meissner, Jennifer Geddes‐McAlister, Matthias Mann, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 637-654
Closed Access | Times Cited: 227
Modulating biomolecular condensates: a novel approach to drug discovery
Diana M. Mitrea, Matthäus Mittasch, Beatriz Ferreira Gomes, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 11, pp. 841-862
Open Access | Times Cited: 225
TF-PROTACs Enable Targeted Degradation of Transcription Factors
Jing Liu, He Chen, H. Ümit Kanıskan, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 23, pp. 8902-8910
Open Access | Times Cited: 176
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Antibody targeting of E3 ubiquitin ligases for receptor degradation
Hadir Marei, Wen‐Ting K. Tsai, Yee-Seir Kee, et al.
Nature (2022) Vol. 610, Iss. 7930, pp. 182-189
Open Access | Times Cited: 157
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 147
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Jun Wang, Xufen Yu, Weida Gong, et al.
Nature Cell Biology (2022) Vol. 24, Iss. 3, pp. 384-399
Open Access | Times Cited: 137
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
Yu Chen, Ira Tandon, William J. Heelan, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 13, pp. 5330-5350
Open Access | Times Cited: 137
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Xufen Yu, Dongxu Li, Jithesh Kottur, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 613
Open Access | Times Cited: 118
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
Jing Gao, Bo Hou, Qiwen Zhu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 116
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 7, pp. 1182-1190
Open Access | Times Cited: 96
Recent Progress of Supramolecular Chemotherapy Based on Host–Guest Interactions
Miaomiao Yan, Sha Wu, Yuhao Wang, et al.
Advanced Materials (2023) Vol. 36, Iss. 21
Closed Access | Times Cited: 94
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 1, pp. 385-391
Closed Access | Times Cited: 87
Accelerated rational PROTAC design via deep learning and molecular simulations
Shuangjia Zheng, Youhai Tan, Zhenyu Wang, et al.
Nature Machine Intelligence (2022) Vol. 4, Iss. 9, pp. 739-748
Closed Access | Times Cited: 77
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 71
Bifunctional Compounds as Molecular Degraders for Integrin-Facilitated Targeted Protein Degradation
Jiwei Zheng, Wanyi He, Jing Li, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 48, pp. 21831-21836
Closed Access | Times Cited: 69
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 69
Aptamer-Based Targeted Protein Degradation
Yuan Liu, Xu Qian, Chunyan Ran, et al.
ACS Nano (2023) Vol. 17, Iss. 7, pp. 6150-6164
Open Access | Times Cited: 47
Dendronized DNA Chimeras Harness Scavenger Receptors To Degrade Cell Membrane Proteins
Chenghong Zhu, Weishan Wang, Yan Wang, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 13
Closed Access | Times Cited: 45
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Yuan Fang, Shuhang Wang, Songzhe Han, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 303-317
Open Access | Times Cited: 45
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
Houssein Chhouri, David Alexandre, Luca Grumolato
Cancers (2023) Vol. 15, Iss. 2, pp. 504-504
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top